Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...
Saved in:
Main Authors: | Vittorio Fusco (Author), Giuseppina Campisi (Author), Paul de Boissieu (Author), Federico Monaco (Author), Anna Baraldi (Author), Gianmauro Numico (Author), Alberto Bedogni (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
by: Noopur Raje, et al.
Published: (2019) -
ZOLEDRONATE-ASSOCIATED RECURRENCE OF OSTEONECROSIS OF JAWS
by: Rosen Tsolov, et al.
Published: (2020) -
Temporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation
by: Giordana Bettini, et al.
Published: (2022) -
<i>ONJ (MRONJ) Update 2021</i>-Osteonecrosis of Jaw Related to Bisphosphonates and Other Drugs-Prevention, Diagnosis, Pharmacovigilance, Treatment: A 2021 Web Event
by: Vittorio Fusco, et al.
Published: (2022) -
Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures
by: Gioacchino Catania, et al.
Published: (2016)